Steven Nissen, MD

216.444.6697

Steven Nissen, MD

Appointed: 1992

Steven Nissen, MD
Department: Cardiovascular Medicine
Department Chair
Location: Cleveland Clinic Main Campus
Mail Code J2-3
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.6697
DeskDesk:216.444.6740
WorkFax:216.445.6855
Steven Nissen, MD
Department: Molecular Cardiology
Location: Cleveland Clinic Main Campus
Mail Code J2-3
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.6697
DeskDesk:216.444.6740
WorkFax:216.445.6855
Surgeon:
No
Treats:
Adults Only

Biographical Sketch

Steven Nissen, MD, is the Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine located on the main campus of Cleveland Clinic. He was appointed in 2006. Prior to this, he served nine years as Vice-Chairman of the Department of Cardiology and five years as Medical Director of the Cleveland Clinic Cardiovascular Coordinating Center (C5), an organization that directs multicenter clinical trials.

Dr. Nissen’s research during the last two decades has focused on the application of intravascular ultrasound (IVUS) imaging for the assessment of progression and regression of coronary atherosclerosis. He has served as International Principal Investigator for several large IVUS multi-center atherosclerosis trials.

Contributions to scientific literature include more than 350 journal articles and 60 book chapters including many manuscripts in NEJM and JAMA. In recent years, he has also written on the subject of drug safety and was the author of manuscripts highlighting concerns about the COX-2 inhibitors (Vioxx™), muraglitazar and rosiglitazone (Avandia™).

Other contributions include current service as editor of Current Cardiology Report, and senior consulting editor to the Journal of the American College of Cardiology.

Dr. Nissen's national positions include:

One-year term as president of the American College of Cardiology (ACC) from March 2006 to March 2007. He served on the ACC Executive Committee 2004-2008. He served 10 years as a member of Board of Trustees of the ACC. He has served several terms on the Program Committee for ACC Annual Scientific Sessions.

Dr. Nissen served as a member of the CardioRenal Advisory Panel of Food and Drug Administration (FDA) for five years, and as chair of the final year of his membership. He continues to serve as a periodic advisor to several FDA committees as a Special Government Employee.

Dr. Nissen is a frequent lecturer before national and international meetings. He has served as visiting professor, or provided Grand Rounds, at nearly 100 institutions.

As a physician/scientist, Dr. Nissen consults for many pharmaceutical companies on the development of new therapies for cardiovascular disease, but maintains his longstanding personal policy of requiring companies to donate all related honoraria directly to charity.

Dr. Nissen is also known for his role in public policy discussions, particularly in the area of drug safety. He has testified in both the Senate and the House of Representatives on this issue as well as the need to reform the Food and Drug Administration (FDA).

Dr. Nissen was selected for the Outstanding Scientist Award by the Cleveland Clinic in 2004. He received the Outstanding Teacher Award, presented by the Fellows of Cardiovascular Medicine, on three occasions.

Dr. Nissen also received Award for Outstanding Contributions to Cardiovascular Research from the Gill Heart Institute of the University of Kentucky in 2004.

In 2007, Dr. Steven Nissen was named by TIME Magazine as "one of the 100 most influential people in the world".

Dr. Nissen was also named in 2007 by SmartMoney Magazine as one of the "country’s 30 most powerful forces in business and finance."

Dr. Nissen earned his medical degree from the University of Michigan School of Medicine in Ann Arbor. He completed Internal Medicine internship and residency at the University of California, Davis in Sacramento, and Cardiology Fellowship at the University of Kentucky Medical Center in Lexington. Dr. Nissen's early career years were spent at the University of Kentucky College of Medicine achieving a rank of Associate Professor.

Professional Highlights

  • Principal Investigator, Global Cardiovascular Innovations Center, Cleveland Clinic, 2006
  • Director, Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic
  • Member, National Institutes of Health Level 1 Working Group on Clinical Trial Design National Heart, Lung, and Blood Institute (NIH), 2006
  • National Government Service:  Presently serves as Special Government Employee as periodic advisor to the U.S. Food and Drug Administration (FDA).
  • Chairman, Cardiovascular Renal Drugs Advisory Committee, Department of Health and Human Resources, U.S. FDA, 2004 - 2005
  • Member, Cardiovascular Renal Drugs Advisory Committee, Department of Health and Human Resources, U.S. FDA, 2000 - 2004
  • Medical Director, Cleveland Clinic Cardiovascular Coordinating Center - an organization that directs multicentric clinical trials, 2001 - 2006

Education & Fellowships

Fellowship - University of Kentucky Chandler Medical Center
Cardiology
Lexington, KY USA
1983
Residency - University of California Davis Medical Center
Internal Medicine
Sacramento, CA USA
1981
Internship - University of California Davis Medical Center
Medical Internship
Sacramento, CA USA
1979
Medical School - University of Michigan Medical School
Ann Arbor, MI USA
1978
Undergraduate - University of Michigan
Ann Arbor, MI USA
1974

Certifications

  • Internal Medicine
  • Internal Medicine- Cardiovascular Disease

Specialty Interests

General cardiology, heart disease, intravascular ultrasound, digital angiography and computer image processing, coronary intensive care

Awards & Honors

  • "100 Most Influential People in the World," TIME Magazine, 2007
  • "Country’s 30 Most Powerful Forces in Business and Finance," Smart Money, 2007
  • President, American College of Cardiology, a 34,000 member, non-profit, professional medical society, whose mission is to advocate for quality cardiovascular care - through education, research promotion, development and application of standards and guidelines - and to influence health care policy, March 2006 thru March 2007
  • Honorary Member of the Japanese College of Cardiology (JCC), 2007
  • Award for Outstanding Contributions to Cardiovascular Research from the Gill Heart Institute of the University of Kentucky, 2004 
  • Outstanding Scientist Award by the Cleveland Clinic, 2004 
  • A number of additional honors and recognitions have been bestowed on Dr. Nissen; on three occasions, he received the Outstanding Teacher Award presented by the Fellows of Cardiovascular Medicine at Cleveland Clinic, 2004, 1998, 1994

Additional Training

  • Intensive Care Units Committee, University of Kentucky Medical Center, 1983-1992
  • Aeromedical Patient Care for the University of Kentucky, 1987-1992
  • Certification - Cardiovascular Medicine, American Board of Internal Medicine, 1983
  • Certification - American Board of Internal Medicine, 1979
  • Certification - National Board of Medical Examiners, 1979

Innovations & Patents

  • Dr. Steven Nissen was one of the pioneers in the development of intravascular ultrasound (IVUS) and his research during the last two decades has focused on this imaging technique. Specifically, he developed the methods used to employ IVUS in the assessment of the progression and regression of coronary atherosclerosis. He has served as principal investigator for 6 major trials using IVUS to assess coronary disease and is currently conducting several additional atherosclerosis studies.
  • Co-chairman, American College of Cardiology  and the European Society of Cardiology International Writing Group to develop an Expert Consensus Document on Standards for the Acquisition, Measurement, and Reporting of Intravascular Ultrasound Studies, 1999-2001 
  • Member, National Joint Committee of the American College of Cardiology and the American Heart Association  to revise 1990 Coronary Angiography Guidelines, 1995-2000 
  • Appointed committee member in the development of CD-ROM Version of the American College of Cardiology Self-Assessment Program (ACC-SAP), 1994-1996
  • Co-chairman Joint Committees of the American College of Cardiology and National Electronics Manufacturers Association for  Digital Imaging and Communication for Medicine (DICOM) Working Group I, Task Force to Develop Standards for Digital Image Archiving  Devices for Cardiac Catheterization Laboratories, 1992-2000

 

Memberships

  • Master of the American College of Cardiology (ACC), March 2006
  • Fellow of the American College of Cardiology, 1987 - 2006  
  • ACC activities include serving as member Board of Trustees twice as well as chairman, co-chairman, member,  ex-officio representative to more than thirty committees, task forces, working and writing groups.
  • Member, Professional Medical Associations (PMA), 2007
  • Member, Association of American Physicians (AAP), 2007
  • Member, Association of Professors of Cardiology (APC), 2006-present
  • Editor, Current Cardiology Reports, 2006 - present
  • Senior Consulting Editor, Journal of the American College of  Cardiology, 2002 - present
  • Dr. Nissen's contributions to scientific literature includes being  member of 12 Editorial Boards for peer review medical journals, as well as providing service as Reviewer to 23 additional Editorial Boards, 1989 - present 

Treatment & Services

Specialty in Diseases and Conditions

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 7/1/2014, Dr. Nissen has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Donation of Financial Interest. Dr. Nissen has consulted for, received compensation for serving as a fiduciary from, or received royalties from the following companies but instructed them to donate all compensation:

  • Novo Nordisk, A/S

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English
Cleveland Clinic Mobile Site